文献速递胃肠外科肝胆胰外科围术期管理与 ERAS

胃肠癌手术医院微创利用率对围术期结局的影响

Hospital Minimally Invasive Surgery Utilization for Gastrointestinal Cancer.
PubMed 文献 · Ann Surg · 2018-01-01

该回顾性队列研究纳入国家癌症数据库2010-2013年137,581例食管、胃、胰腺、肝胆、结肠和直肠癌手术切除患者,计算疾病特异性医院层面微创利用率。多数医院为低利用率(≤30%),较高微创利用率与更多淋巴结检出、更短住院时间、辅助化疗间隔缩短相关,结肠癌和直肠癌中与死亡风险降低相关。

要点

  • 多数收治胃肠恶性肿瘤的医院微创利用率低(≤30%病例)。
  • 较高微创利用率与更多淋巴结检出和更短住院时间相关。
  • 结肠癌和直肠癌中,较高微创利用率与死亡风险降低相关。

核心结论

  • 多数治疗胃肠恶性肿瘤的医院为低微创利用率医院。
  • 研究结果可能反映真实世界中微创手术用于肿瘤切除的有效性。

研究设计与样本

  • 回顾性队列研究,纳入国家癌症数据库2010-2013年137,581例手术切除的食管、胃、胰腺、肝胆、结肠和直肠癌患者。
  • 计算疾病特异性、医院层面、可靠性调整的微创利用率以评估围术期结局。

主要发现

  • 疾病特异性微创使用率随时间显著增加(增幅42.0%-68.3%,趋势检验除肝胆外P<0.001,肝胆P=0.007)。
  • 多数医院为低利用率(≤30%病例),范围从结肠癌30.3%到胰腺癌92.9%。
  • 较高微创利用率与更多淋巴结检出(所有P<0.001)和更短住院时间(所有P<0.001)相关。
  • 微创利用率每增加10%,与辅助化疗天数减少相关:MIS胃癌3.3天(95%CI 1.2-5.3),开放胃癌3.3天(95%CI 0.7-5.8),开放结肠癌1.1天(95%CI 0.3-2.0)。
  • 微创利用率与死亡风险关联见于结肠癌(Q2 HR 0.96,95%CI 0.89-1.02;Q3 HR 0.91,95%CI 0.86-0.98;Q4 HR 0.87,95%CI 0.82-0.93)和直肠癌(Q2 HR 0.89,95%CI 0.76-1.05;Q3 HR 0.84,95%CI 0.82-0.97;Q4 HR 0.86,95%CI 0.74-0.98)。

临床怎么用

  • 选择微创利用率较高的医院可能有助于改善胃肠癌手术的围术期结局和辅助化疗及时性。
  • 医院微创利用率可作为识别具备有益多学科癌症诊疗基础设施或流程的参考指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of the study was to evaluate the impact of receiving care at high minimally invasive surgery (MIS)-utilizing hospitals BACKGROUND:: MIS techniques are used across surgical specialties. The extent of MIS utilization for gastrointestinal (GI) cancer resection and impact of receiving care at high utilizing hospitals is unclear. METHODS: This is a retrospective cohort study of 137,581 surgically resected esophageal, gastric, pancreatic, hepatobiliary, colon, and rectal cancer patients within the National Cancer Data Base (2010-2013). Disease-specific, hospital-level, reliability-adjusted MIS utilization rates were calculated to evaluate perioperative outcomes. Among patients for whom adjuvant chemotherapy (AC) was indicated, the association between days to AC and hospital MIS utilization was examined using generalized estimating equations. Association with risk of death was evaluated using multivariable Cox regression. RESULTS: Disease-specific MIS use increased significantly [42.0%-68.3% increase; trend test, P < 0.001 for all except hepatobiliary (P = 0.007)] over time. Most hospitals [range-30.3% (colon); 92.9% (pancreatic)] were low utilizers (≤30% of cases). Higher MIS utilization is associated with increased lymph nodes examined (P < 0.001, all) and shorter length of stay (P < 0.001, all). Each 10% increase in MIS utilization is associated with fewer days to AC [3.3 (95% confidence interval, 1.2-5.3) for MIS gastric; 3.3 ([0.7-5.8) for open gastric; 1.1 (0.3-2.0) days for open colon]. An association between MIS utilization and risk of death was observed for colon [Q2-hazard ratio (HR) 0.96 (0.89-1.02); Q3-HR 0.91 (0.86-0.98); Q4-HR 0.87 (0.82-0.93)] and rectal cancer [Q2-HR 0.89 (0.76-1.05); Q3-HR 0.84 (0.82-0.97); Q4-HR 0.86 (0.74-0.98)]. CONCLUSIONS: Most hospitals treating GI malignancies are low MIS utilizers. Our findings may reflect real-world MIS effectiveness for oncologic resection and could be useful for identifying hospitals with infrastructure and/or processes beneficial for multimodality cancer care.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Mason MC, Tran Cao HS, Awad SS, et al. Hospital Minimally Invasive Surgery Utilization for Gastrointestinal Cancer. Ann Surg. 2018. PMID: 28498235. doi:10.1097/SLA.0000000000002302

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。